Fifty 1 Labs, Inc. and The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study, Unlocking Pathways for Gene-Based and Repurposed Therapies
Fifty1 AI Labs (OTC:FITY) has completed the world's largest and most comprehensive Sickle Cell Disease (SCD) study, backed by The Gates Foundation. The groundbreaking research analyzed a decade of real-world patient data, creating an unprecedented mapping of disease progression and treatment outcomes.
The study, conducted in collaboration with the University of Pittsburgh School of Medicine and Stellenbosch University Centre, aims to accelerate the development of gene-based therapies and repurposed medicines. The research findings will be presented at a specialist conference in Senegal and have been submitted to a leading hematology journal.
With 7.74 million people worldwide affected by SCD, primarily in sub-Saharan Africa, this AI-driven analysis represents a significant step toward developing affordable treatments for this underserved genetic disorder.
Fifty1 AI Labs (OTC:FITY) ha completato il più ampio e dettagliato studio al mondo sulla Sickle Cell Disease (SCD), sostenuto da The Gates Foundation. La ricerca, all'avanguardia, ha analizzato un decennio di dati real-world dei pazienti, realizzando una mappatura senza precedenti dell'evoluzione della malattia e degli esiti terapeutici.
Lo studio, condotto in collaborazione con la University of Pittsburgh School of Medicine e il Stellenbosch University Centre, mira ad accelerare lo sviluppo di terapie geniche e il riposizionamento di farmaci esistenti. I risultati saranno presentati a una conferenza specialistica in Senegal e sono stati sottoposti a una rivista leader in ematologia.
Con circa 7,74 milioni di persone colpite nel mondo, soprattutto nell'Africa subsahariana, questa analisi basata sull'IA rappresenta un passo importante verso lo sviluppo di trattamenti accessibili per questa patologia genetica spesso trascurata.
Fifty1 AI Labs (OTC:FITY) ha completado el mayor y más exhaustivo estudio mundial sobre la Sickle Cell Disease (SCD), con el apoyo de The Gates Foundation. Esta investigación pionera analizó una década de datos reales de pacientes y ha trazado, sin precedentes, la progresión de la enfermedad y los resultados de los tratamientos.
El estudio, realizado en colaboración con la University of Pittsburgh School of Medicine y el Stellenbosch University Centre, pretende acelerar el desarrollo de terapias génicas y la reutilización de medicamentos ya existentes. Los hallazgos se presentarán en una conferencia especializada en Senegal y se han enviado a una revista líder en hematología.
Con aproximadamente 7,74 millones de personas afectadas en el mundo, principalmente en el África subsahariana, este análisis impulsado por IA supone un avance relevante hacia tratamientos asequibles para este trastorno genético desatendido.
Fifty1 AI Labs (OTC:FITY)가 The Gates Foundation의 지원을 받아 세계에서 가장 크고 포괄적인 겸상적혈구병(SCD) 연구를 완료했습니다. 이 획기적인 연구는 10년간의 실제 환자 데이터를 분석해 질병 진행과 치료 결과를 전례 없이 상세히 도식화했습니다.
해당 연구는 University of Pittsburgh School of Medicine 및 Stellenbosch University Centre와 협력해 진행되었으며, 유전자 기반 치료법과 기존 약물의 재목적화를 가속화하는 것을 목표로 합니다. 연구 결과는 세네갈의 전문 학회에서 발표될 예정이며 주요 혈액학 저널에 제출되었습니다.
전 세계 약 774만 명이 이 질환으로 고통받고 있으며 주로 사하라 이남 아프리카에 집중되어 있습니다. 이번 AI 기반 분석은 이 소외된 유전 질환에 대해 접근 가능한 치료법 개발로 나아가는 중요한 진전입니다.
Fifty1 AI Labs (OTC:FITY) a mené la plus vaste et la plus complète étude mondiale sur la Sickle Cell Disease (SCD), soutenue par The Gates Foundation. Cette recherche innovante a analysé une décennie de données patients réelles, établissant une cartographie inédite de la progression de la maladie et des résultats des traitements.
L'étude, réalisée en collaboration avec la University of Pittsburgh School of Medicine et le Stellenbosch University Centre, vise à accélérer le développement de thérapies géniques et le repositionnement de médicaments existants. Les conclusions seront présentées lors d'une conférence spécialisée au Sénégal et ont été soumises à une revue majeure d'hématologie.
Avec environ 7,74 millions de personnes touchées dans le monde, principalement en Afrique subsaharienne, cette analyse pilotée par l'IA représente une avancée significative vers des traitements abordables pour ce trouble génétique peu pris en charge.
Fifty1 AI Labs (OTC:FITY) hat die weltweit größte und umfassendste Studie zur Sickle Cell Disease (SCD) abgeschlossen, unterstützt von The Gates Foundation. Die bahnbrechende Untersuchung wertete ein Jahrzehnt realer Patientendaten aus und erstellte eine beispiellose Kartierung des Krankheitsverlaufs und der Behandlungsergebnisse.
Die Studie, durchgeführt in Zusammenarbeit mit der University of Pittsburgh School of Medicine und dem Stellenbosch University Centre, zielt darauf ab, die Entwicklung gentherapeutischer Ansätze und das Repurposing vorhandener Medikamente zu beschleunigen. Die Ergebnisse werden auf einer Fachkonferenz in Senegal vorgestellt und einer führenden hämatologischen Fachzeitschrift zur Veröffentlichung eingereicht.
Mit rund 7,74 Millionen Menschen weltweit, vor allem in Subsahara-Afrika, stellt diese KI-gestützte Analyse einen wichtigen Schritt zur Entwicklung erschwinglicher Behandlungen für diese bislang unterversorgte genetische Erkrankung dar.
- Collaboration with prestigious partners including The Gates Foundation and major research institutions
- AI technology successfully analyzed a decade of real-world patient data
- Research could accelerate development of new treatments through gene therapy and drug repurposing
- Addresses large market opportunity with 7.74 million affected patients globally
- No immediate revenue generation from the research
- Timeline for developing actual treatments remains uncertain
- Significant competition in gene therapy and drug development space
Landmark AI-driven analysis backed by The Gates Foundation sets stage for transformative treatments in one of the world's most underserved diseases
VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, Inc. (OTC: FITY), a leader in AI-powered drug repurposing and precision medicine, today announced the completion of the largest and most comprehensive study of Sickle Cell Disease (SCD) ever undertaken. Leveraging a decade's worth of real-world patient data, the study mapped disease progression and treatment outcomes at an unprecedented scale—marking a major milestone in the fight against this life-threatening genetic disorder.
Funded by The Gates Foundation and conducted in collaboration with scientists from the University of Pittsburgh School of Medicine and the Stellenbosch University Centre for Infectious Diseases in South Africa, the groundbreaking research delivers the most detailed understanding to date of SCD's clinical landscape.
"This is more than a scientific achievement—it's a turning point," said Paul Arora, CEO of Fifty1 AI Labs. "By combining AI-driven analytics with world-class partnerships, we are accelerating the path toward affordable, effective treatments for millions who have long been overlooked."
The study's findings have been submitted to one of the world's most respected hematology journals and will be presented this September at a specialist conference in Senegal, drawing leading global experts in blood disorders.
Beyond its academic and clinical impact, the study serves as a catalyst for next-generation gene-based therapies and the repurposing of existing medicines—two approaches that can dramatically shorten timelines and reduce costs in bringing new treatments to market. With an estimated 7.74 million people worldwide living with SCD—most in sub-Saharan Africa and among people of African descent—this work addresses one of the highest-burden, least-served health challenges globally.
Powered by advanced analytics technologies pioneered at Fifty1 AI Labs, the project demonstrates how AI can mine real-world clinical data at scale, uncovering insights that can transform treatment strategies across multiple disease areas.
About Fifty1 AI Labs, Inc.
Fifty1 AI Labs is revolutionizing drug development through AI-driven analytics, focusing on uncovering novel therapeutic applications for existing drugs and developing precision medicine solutions. The company's platform integrates large-scale clinical, genomic, and patient outcome data to accelerate treatment innovation across global health challenges.
Contact:
Investor Relations
Fifty 1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1AIlabs.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of gene-based therapies and repurposed treatments for Sickle Cell Disease, the anticipated presentation of study findings at a specialist conference, and the ability of Fifty1 AI Labs' platform to transform treatment strategies across multiple disease areas, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of clinical trials, regulatory approvals, the efficacy and safety of potential treatments, and the company's ability to successfully develop and commercialize its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, please refer to Fifty1 AI Labs' filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
FAQ
What is the significance of Fifty1 AI Labs' (OTC:FITY) Sickle Cell Disease study?
Who are the key partners in Fifty1 AI Labs' SCD research?
How many people could benefit from Fifty1 AI Labs' SCD research?
When will Fifty1 AI Labs (FITY) present their SCD study findings?
How does Fifty1 AI Labs' technology contribute to SCD research?
